GEA
KPTI icon

Glen Eagle Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Glen Eagle Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40
Closed -$3.49K – 1016
2021
Q3 		$3.49K Sell
40
-7
-15% -$727 ﹤0.01% 853
2021
Q2 		$7.22K Sell
47
-7
-13% -$1.02K ﹤0.01% 757
2021
Q1 		$8.52K Hold
54
– – ﹤0.01% 688
2020
Q4 		$12.5K Buy
54
+7
+15% +$1.62K ﹤0.01% 594
2020
Q3 		$10.4K Buy
47
+24
+104% +$5.87K ﹤0.01% 590
2020
Q2 		$6.44K Buy
+23
New +$6.8K ﹤0.01% 629

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Glen Eagle Advisors's KPTI Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 40 shares — an estimated $3.49K sold.

Glen Eagle Advisors first reported a position in KPTI in Q2 2020 and held it in 6 quarters. The position peaked at $12.5K in Q4 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 40 Karyopharm Therapeutics shares in Q4 2021, an estimated $3.49K.
  • Glen Eagle Advisors first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 6 quarters.
  • Glen Eagle Advisors's Karyopharm Therapeutics position peaked at $12.5K in Q4 2020.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.